The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis Market.

Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years. 
• Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutici, CSL Behring, Haisco Pharmaceutical Group, SolAeroMed Inc., AstraZeneca, Zambon SpA, Insmed Incorporated, Zambon, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, Haisco Pharmaceutical, and others, are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment 

• Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, NCFB, mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, Brensocatib, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, HSK31858, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years.   
• In April 2022, For people with non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa, the FDA designated colistethate sodium powder for nebulization as a breakthrough treatment to reduce pulmonary exacerbations. In December 2022, A trial titled “Phase 2 Randomised, Doubleblind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-cystic FibrosisBronchiectasis” was started by Haisco Pharmaceutical Group Co., Ltd.
• In February 2022, A randomised, double-blind, placebo-controlled, two-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of single and multiple oral doses of HSK31858 in healthy volunteers was started by Haisco Pharmaceutical Group Co., Ltd
• In September 2021, At the European Respiratory Society Congress, Zambon presented the Phase III PROMIS-I study’s final findings. CMS I-neb significantly decreased the annual rate of exacerbations and severe exacerbations in patients with NCFB, according to the study, which looked at the use of CMS powder for nebulizer solution delivered by the I-neb AAD system (hereafter referred to as “CMS I-neb”)

Non-Cystic Fibrosis Bronchiectasis Overview

The progressive respiratory condition known as non-cystic fibrosis (non-CF) bronchiectasis, also known simply as bronchiectasis, is characterised by mucus accumulation, persistent bronchial dilatation, and impaired ciliary clearance. Chronic daily sputum, coughing, shortness of breath, and recurrent respiratory infections are among the clinical symptoms, which increase morbidity and degrade quality of life.

Get a Free Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include:

• NP339: NovaBiotics Ltd
• Research Programme: NCFB:  Synspira Therapeutics
• Research programme: mucolytic agents: Parion Sciences
• CHF 6333: Chiesi Farmaceutici
• CSL787: CSL Behring
• HSK31858: Haisco Pharmaceutical Group
• S-1226: SolAeroMed Inc.
• Benralizumab: AstraZeneca
• Colistimethate sodium: Zambon SpA
• Brensocatib: Insmed Incorporated/AstraZeneca
• HSK31858: Haisco Pharmaceutical Group Co., Ltd.
• Colistimethate sodium: Zambon
• BI 1291583: Boehringer Ingelheim
• AP-PA02: Armata Pharmaceuticals
• ARINA-1: Renovion
• HSK31858: Haisco Pharmaceutical

Route of Administration

Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal antibody
• Small molecule
• Peptide

Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment

• Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type
• Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type
• Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration
• Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration
• Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type
• Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type

DelveInsight’s Non-Cystic Fibrosis Bronchiectasis Report covers around 17+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies

Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include:

Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are – Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, Haisco Pharmaceutical, and others.

Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis:

The Non-Cystic Fibrosis Bronchiectasis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment.
• Non-Cystic Fibrosis Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies

Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers

• Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market.

Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers

• However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth.

Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight    

• Coverage: Global
• Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutici, CSL Behring, Haisco Pharmaceutical Group, SolAeroMed Inc., AstraZeneca, Zambon SpA, Insmed Incorporated, Zambon, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, Haisco Pharmaceutical, and others
• Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, NCFB, mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, Brensocatib, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, HSK31858, and others
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies
• Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers 

Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services